BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25686823)

  • 1. SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression.
    Esposito S; Russo MV; Airoldi I; Tupone MG; Sorrentino C; Barbarito G; Di Meo S; Di Carlo E
    Oncotarget; 2015 Jul; 6(19):17121-34. PubMed ID: 25686823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis.
    Russo MV; Esposito S; Tupone MG; Manzoli L; Airoldi I; Pompa P; Cindolo L; Schips L; Sorrentino C; Di Carlo E
    Oncotarget; 2016 Mar; 7(11):12372-85. PubMed ID: 26540632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ID1-, ID2-, and ID3-regulated gene expression in E2A positive or negative prostate cancer cells.
    Asirvatham AJ; Carey JP; Chaudhary J
    Prostate; 2007 Sep; 67(13):1411-20. PubMed ID: 17639499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
    Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
    Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.
    Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ
    PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
    Uygur B; Abramo K; Leikina E; Vary C; Liaw L; Wu WS
    Prostate; 2015 Jun; 75(9):907-16. PubMed ID: 25728608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25.
    Liang H; Studach L; Hullinger RL; Xie J; Andrisani OM
    Exp Cell Res; 2014 Jan; 320(2):188-99. PubMed ID: 24135225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
    Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
    Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-181a suppresses salivary adenoid cystic carcinoma metastasis by targeting MAPK-Snai2 pathway.
    He Q; Zhou X; Li S; Jin Y; Chen Z; Chen D; Cai Y; Liu Z; Zhao T; Wang A
    Biochim Biophys Acta; 2013 Nov; 1830(11):5258-66. PubMed ID: 23911747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
    Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
    Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines.
    Emadi Baygi M; Soheili ZS; Essmann F; Deezagi A; Engers R; Goering W; Schulz WA
    Tumour Biol; 2010 Aug; 31(4):297-307. PubMed ID: 20506051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer.
    Atmaca A; Wirtz RW; Werner D; Steinmetz K; Claas S; Brueckl WM; Jäger E; Al-Batran SE
    BMC Cancer; 2015 Apr; 15():300. PubMed ID: 25928859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
    Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
    Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development.
    Wu K; Zeng J; Zhou J; Fan J; Chen Y; Wang Z; Zhang T; Wang X; He D
    Urol Oncol; 2013 Nov; 31(8):1751-60. PubMed ID: 22421353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
    Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG.
    Chen M; Chen LM; Chai KX
    Prostate; 2006 Jun; 66(9):911-20. PubMed ID: 16541421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.
    Tawadros T; Alonso F; Jichlinski P; Clarke N; Calandra T; Haefliger JA; Roger T
    Endocr Relat Cancer; 2013 Feb; 20(1):137-49. PubMed ID: 23207293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition.
    Liang W; Hao Z; Han JL; Zhu DJ; Jin ZF; Xie WL
    Urol Oncol; 2014 Aug; 32(6):855-63. PubMed ID: 24968949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
    Gururajan M; Cavassani KA; Sievert M; Duan P; Lichterman J; Huang JM; Smith B; You S; Nandana S; Chu GC; Mink S; Josson S; Liu C; Morello M; Jones LW; Kim J; Freeman MR; Bhowmick N; Zhau HE; Chung LW; Posadas EM
    Oncotarget; 2015 Dec; 6(42):44072-83. PubMed ID: 26624980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.